Aura Biosciences Inc. (AURA)
AURA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AURA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001501796 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $41.7M cash; operating cash flow -$27.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 104,074,302 (2026-11-04); 63,503,269 a year earlier; 38,259,879 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $40.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$32.1M | -$26.4M | $41.7M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$45.6M | -$32.5M | $67.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$33.7M | -$29.9M | $84.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$25.6M | -$20.5M | $59.5M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$26.1M | -$20.1M | $47.6M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$27.0M | -$20.8M | $107.4M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$27.5M | -$23.4M | $38.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$25.8M | -$24.0M | $31.7M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-11 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-06-29 |
Source: SEC EDGAR submissions feed, 387 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.4% |
| 1 month | +13.4% |
| 3 months | -7.1% |
| Year to date | +30.5% |
| 1 year | +28.6% |
| From 52-week high | -20.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PRME | Prime Medicine Inc. | $4.19 | -1.87% | $762.3M |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.16 | -2.24% | $782.7M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | -2.68% | $673.1M |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
| DBVT | DBV Technologies S.A. | $10.27 | -6.76% | $645.8M |
| BBTX | Bambusa Therapeutics Inc. | $15.98 | -0.68% | $645.4M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier